Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust

Hospital


Location: London, United Kingdom (GB) GB

ISNI: 0000000404170461

ROR: https://ror.org/034vb5t35

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Online Magnetic Resonance-Guided Radiotherapy (oMRgRT) for Gynecological Cancers (2021) Portelance L, Corradini S, Erickson B, Lalondrelle S, Padgett K, van der Leij F, van Lier A, Jürgenliemk-Schulz I Journal article, Review article The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review (2021) Dahn HM, Boersma LJ, de Ruysscher D, Meattini I, Offersen BV, Pignol JP, Aristei C, et al. Journal article, Review article ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology (2021) Corradini S, Alongi F, Andratschke N, Azria D, Bohoudi O, Boldrini L, Bruynzeel A, et al. Journal article High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE (2021) Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, Song C, et al. Conference contribution Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients (2020) Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, Breuing J, et al. Journal article, Review article Prognostic gene expression signature for high-grade serous ovarian cancer (2020) Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, et al. Journal article
1 ... 3 4 5 6 7 8